BREAKING NEWS: BREAKTHROUGH FOR EBOLA VIRUS DISEASE AS US SCIENTIST PROPOSED NEW DRUG DISCOVERY SAVE LIVES OF 2 INFECTED DOCTORS

PHOTO: THE TWO MISSIONARY DOCTORS RESPONDING TO NEW EBOLA VIRUS DRUG.

I happened to do a Research Seminar on Ebola Virus Disease about 2 month before if entered Nigeria and during the course of my research, I got a mail from a friend currently doing a Virology Training in a biotech firm, Mapp Biopharmaceutical Inc. The mail was  about an unpublished journal report of a work done on Ebola Virus by above mentioned scientific research firm in San Diego. The Report stated that "ZMapp SERUM" has been found to cure Ebola virus but only in monkeys. They team of scientists mentioned that only monkeys infected from the time of infection to about 2 days were cured and that improvements are still being made on the drug.

Just yesterday after we received sad news that the doctor who treated the Ebola Virus infected Liberian has also been diagnosed with the infection,  Dr. Sanjay Gupta for CNN Published an article saying that an experimental drug called ZMapp likely saved the lives of 2 US missionary doctors (pictured above). Below is the report from CNN.

Three vials containing an experimental drug stored at subzero temperatures were flown into Liberia last weekin a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.
The drug appears to have worked, sources say. Dr. Kent Brantly's and Nancy Writebol's conditions significantly improved after receiving the medication, sources say. Brantly was able to walk into Emory University Hospital in Atlanta after being evacuated to the United States last week, and Writebol is expected toarrive in Atlanta on Tuesday.
On July 22, Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.It's believed both Brantly and Writebol, who worked with the aid organization Samaritan's Purse, contracted Ebola from another health care worker at their hospital in Liberia, although the official Centers for Disease Control and Prevention case investigation has yet to be released.A representative from the National Institutes of Health contacted Samaritan's Purse in Liberia and offered the experimental treatment, known as ZMapp, for the two patients, according to the source.
The drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The patients were told that this treatment had never been tried before in a human being but had shown promise in small experiments with monkeys.
According to company documents, four monkeys infected with Ebola survived after being given the therapy within 24 hours after infection. Two of four other monkeys that started therapy within 48 hours after infection also survived.
One monkey that was not treated died within five days of exposure to the virus.Brantly and Writebol were aware of the
risk of taking a new, little understood treatment and gave informed consent, according to two sources familiar with the care of the missionary workers.
In the monkeys, the experimental serum had been given within 48 hours of infection. Brantly didn't receive it until he'd been sick for nine days.
The medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine. It works by preventing the virus from entering and infecting new cells.
The Ebola virus causes viral hemorrhagic fever, which refers to a group of viruses that affect multiple organ systems in the body and are often accompanied by bleeding.Early symptoms include sudden onset of fever, weakness, muscle pain, headaches and a sore throat.
They later progress to vomiting, diarrhea, impaired kidney and liver function -- and sometimes internal andexternal bleeding.
The ZMapp vials reached the hospital in Liberia where Brantly and Writebol were being treated Thursday morning. Doctors were instructed to allow the serum to thaw naturally without any additional heat. It was expected that it would be eight to 10 hours before the medicine could be given, according to a source familiar with the process.
Brantly asked that Writebol be given the first dose because he was younger and he thought he had a better chance of fighting it, and she agreed.
However, as the first vial was still thawing, Brantly's condition took a sudden turn for the worse.Brantly began to deteriorate and developed labored breathing. He told his doctors he thought he was dying, according to a source with firsthand knowledge of the situation.Knowing his dose was still frozen, Brantly asked if he could have Writebol's now-thawed medication. It was brought to his room and administered through an IV. Within an hour of receiving the medication, Brantly's condition dramatically improved. He began breathing easier; the rash over his trunk faded away. One of his doctors described the events as "miraculous."By the next morning, Brantly was able to take a shower on his own before getting on a specially designed Gulf stream air ambulance jet to be evacuated to the United States.
Writebol also received a vial of the medication. Her response was not as remarkable, according to sources familiar with the treatment. However, doctors on Sunday administered Writebol a second dose of the medication, which resulted in significant improvement.She was stable enough to be evacuated back to the United States and is expected to arrive before noon Tuesday.
The process by which the medication was made available to Brantly and Writebol is highly unusual. ZMapp has not been approved for human use, and has not even gone through the clinical trial process, which is standard to prove the safety and efficacy of a medication. It may have been given under the U.S. Food and Drug Administration's "compassionate use" regulation, which allows access to investigational drugs outside clinical trials.